STOCKHOLM, SWEDEN November 8, 2023. Karolinska Development AB today announces that its portfolio company Modus Therapeutics has decided to carry out a rights issue that can raise up to approximately.
STOCKHOLM, SWEDEN November 8, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has.
Karolinska Development s portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
(1)
STOCKHOLM, SWEDEN - March 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a clinical development program of its drug candidate sevuparin in patients suffering from sepsis/septic shock, and possibly also other severe inflammatory conditions arising in conjunction with major trauma, surgery, autoimmunity and viral infections. Modus Therapeutics expects to start the first clinical trial in this new indication around the end of 2021. Sevuparin has already demonstrated a favorable safety profile in clinical trials for other indications.
Patients suffering from sepsis are at risk of developing septic shock and multi-organ failure. Septic shock is a leading cause of death in intensive care units, with mortality rates typically exceeding 30 percent. There is currently no specific pharmaceutical treatment available for the treatment of sepsis. As a result, it is one of the costliest conditions to tre